ABBV
🚀 AbbVie is entering the competitive weight loss market by acquiring a next-generation obesity drug from Gubra.
💰 The deal involves a significant upfront payment and potential milestone payments.
💪 AbbVie aims to compete with Eli Lilly and Novo Nordisk in a market expected to reach $130 billion in annual sales by 2030.
❓ The analyst questions whether the high initial price is justified, given the crowded market.
@bernardodegarcia:
“AbbVie agreed to pay up to $2.2 billion for a next-generation obesity drug from Danish biotech Gubra, marking its entry into the hyper-competitive weight loss market. The license agreement could see the U.S. pharmaceutical company compete with Eli Lilly and Novo Nordisk, the current leaders in a market expected to reach $130 billion in annual sales by 2030. AbbVie agreed to pay Gubra $350 million upfront, plus up to $1.88 billion in development and commercialization milestone payments, as well as royalties. Gubra’s experimental drug, Gami, mimics amylin, an intestinal hormone somewhat different from GLP-1, which is the backbone of Novo Nordisk’s and Eli Lilly’s market treatments. The potentially less crowded space may explain the high initial price that AbbVie paid for the agreement, said John Murphy, an analyst from, I don’t know who he is an analyst from.”
Watch the exact part of the video where Bernardo talks about AbbVie here:
Watch the video on YouTube.
Read more articles featuring the most recent analysis of AbbVie (ABBV) at this link: ABBV stock.
